乳腺癌骨转移女性中每12周与每4周唑来膦酸给药的持续治疗效应:OPTIMIZE-2随机临床试验
OPTIMIZE-2研究为前瞻性、随机、双盲、多中心3期试验,纳入416例既往接受过9剂以上唑来膦酸和/或帕米膦酸二钠的乳腺癌骨转移女性,1:1随机接受每4周或每12周4.0 mg静脉唑来膦酸治疗1年。每12周组SRE发生率23.2% vs 每4周组22.0%,差异-1.2%(单侧97.5%CI下限-9.8%,非劣效P=0.02),每12周方案在SRE比例上非劣效于每4周方案。
要点
- 每12周唑来膦酸在SRE比例上非劣效于每4周方案(非劣效P=0.02)。
- 首次SRE时间两组无统计学显著差异(HR 1.06;95%CI 0.70-1.60;P=0.79)。
- 每4周组与每12周组安全性特征相当,至少1项不良事件分别为95.5% vs 93.5%。
核心结论
- 每12周唑来膦酸方案在经历1次及以上SRE的患者比例上非劣效于每4周方案。
- 这些结果可能对当前乳腺癌骨转移患者的临床实践产生实质性影响。
研究设计与样本
- OPTIMIZE-2为前瞻性、随机、双盲、多中心3期试验,采用意向治疗(全分析集)、可评估(符合方案)及安全性人群。
- 患者按1:1随机接受每4周或每12周4.0 mg静脉唑来膦酸,中间输注给予安慰剂,治疗1年。
- 研究在美国102个临床试验中心开展,时间为2006年3月3日至2013年7月25日,数据分析时间为2013年10月7日至2014年3月24日。
- 共随机416例(≥18岁)乳腺癌骨转移女性,既往在初始10至15个月治疗中接受过9剂及以上唑来膦酸和/或帕米膦酸。
主要发现
- 1年随访后,每4周组44例(22.0%)发生SRE,每12周组47例(23.2%)发生SRE,比例差异为-1.2%(两组SRE率差异的单侧97.5%CI下限为-9.8%;非劣效P=0.02)。
- 两组首次SRE时间无统计学显著差异(HR 1.06;95%CI 0.70-1.60;P=0.79)。
- 每4周组与每12周组平均(SD)SMR分别为0.46(1.06) vs 0.50(1.50)事件/年(P=0.85)。
- 每4周组189例(95.5%)至少发生1项不良事件,每12周组189例(93.5%),安全性特征相当。
关键数值与推荐
- 每12周方案在SRE比例上非劣效于每4周方案(非劣效P=0.02)。
- 首次SRE时间:HR 1.06(95%CI 0.70-1.60;P=0.79),无统计学显著差异。
- SMR:每4周组0.46(1.06) vs 每12周组0.50(1.50)事件/年(P=0.85)。
临床怎么用
- 原文结论指出每12周唑来膦酸方案在SRE比例上非劣效于每4周方案,这些结果可能对当前乳腺癌骨转移患者的临床实践产生实质性影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Zoledronic acid, a potent bisphosphonate, is commonly administered to patients with bone metastases to reduce the risk of skeletal-related events (SREs). However, there have been concerns regarding its long-term monthly administration. OBJECTIVE: To examine whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastatic breast cancer that involved the bone who had previously received a standard dosing regimen of zoledronic acid and/or pamidronate disodium. DESIGN, SETTING, AND PARTICIPANTS: OPTIMIZE-2 was a prospective, randomized, double-blind, multicenter phase 3 trial of intention-to-treat (full analysis set), evaluable (per protocol), and safety populations. Patients were randomized (1:1) to receive 4.0 mg of intravenous zoledronic acid every 4 or every 12 weeks with placebo for interim infusions for 1 year. The study was conducted at 102 clinical trial centers in the United States from March 3, 2006, to July 25, 2013. Data analysis was performed from October 7, 2013, to March 24, 2014. The study randomized 416 women (≥18 years old) with bone metastases from breast cancer who previously received 9 or more doses of zoledronic acid and/or pamidronate during the first 10 to 15 months of therapy. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients with 1 or more SRE on study (SRE rate). The key secondary end points included time to first SRE and skeletal morbidity rate (SMR). RESULTS: A total of 416 women were randomized: 200 patients received zoledronic acid every 4 weeks (mean [SD] age, 59.2 [11.1] years; 173 were white [86.5%]), 203 patients received zoledronic acid every 12 weeks (mean [SD] age, 58.6 [11.2] years; 178 were white [87.7%]), and 13 patients received placebo (mean [SD] age, 60.8 [12.2] years; 13 were white [100%]). Baseline characteristics were similar in both zoledronic acid treatment arms. After 1 year of follow-up, SREs occurred in 44 patients (22.0%) in the zoledronic acid every 4 weeks group and 47 patients (23.2%) in the zoledronic acid every 12 weeks group (proportional difference of -1.2%; 1-sided 97.5% CI bound of the difference in SRE rate between arms, -9.8%; noninferiority P = .02). The time to first SRE between treatment groups was not statistically significantly different (hazard ratio [HR], 1.06; 95% CI, 0.70-1.60; P = .79). The mean (SD) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in the every 4 weeks vs every 12 weeks groups (P = .85). The safety profiles of the every 4 weeks and every 12 weeks groups were comparable, with 189 patients (95.5%) in the every 4 weeks group having at least 1 adverse event compared with 189 (93.5%) in the every 12 weeks group. CONCLUSIONS AND RELEVANCE: The every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for the proportion of patients experiencing 1 or more SRE. These results may have a substantial influence on current clinical practice for treatment of patients with bone metastasis from breast cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00320710.
引用
- Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28125763. doi:10.1001/jamaoncol.2016.6316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。